SCHEMBL22927481

SCHEMBL22927481

Cc1cc(C(F)F)nn1CC(C)(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.39
KDM4E B2RXH2 4/20 0.39
MAPT P10636 2/20 0.39
HPGD P15428 2/20 0.39
GLA P06280 1/20 0.32
GLS O94925 1/20 0.32
TDP1 Q9NUW8 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
LMNA P02545 2/20 0.30
APAF1 O14727 1/20 0.30
POLB P06746 1/20 0.30
PKM P14618 1/20 0.30
MEN1 O00255 1/20 0.30
CYP1A2 P05177 1/20 0.30
CYP3A4 P08684 1/20 0.30
CYP2D6 P10635 1/20 0.30
CYP2C9 P11712 1/20 0.30
TSHR P16473 1/20 0.30
CYP2C19 P33261 1/20 0.30
HTT P42858 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21471163 0.79 ALDH1A1 (0.42) ALDH1A1KDM4EMAPTHPGDGLA
SCHEMBL13616897 0.76 ALDH1A1 (0.55) ALDH1A1KDM4EGLAGLSLMNA
SCHEMBL21471165 0.76 LMNA (0.41) ALDH1A1KDM4EMAPTHPGDGLA
SCHEMBL24350762 0.76 ADORA2A (0.42) ALDH1A1KDM4EMAPTHPGDGLA
SCHEMBL23194582 0.74 LMNA (0.33) ALDH1A1KDM4EGLAGLSLMNA
SCHEMBL23264160 0.73 NPC1 (0.36) ALDH1A1KDM4EMAPTHPGD
SCHEMBL17321053 0.72 PDE2A (0.35) ALDH1A1KDM4EGLAGLSLMNA
SCHEMBL23194587 0.71 KDM4E (0.34) ALDH1A1KDM4EMAPTHPGDGLA
SCHEMBL21462698 0.71 LMNA (0.64) ALDH1A1KDM4EMAPTHPGDTDP1
SCHEMBL16224892 0.71 ALDH1A1 (0.52) ALDH1A1KDM4EMAPTHPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210024503-A1 4-OXO-3,4-DIHYDROQUINAZOLINE COMPOUNDS AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV Healthcare UK (No.5) Limited (GB) 2021-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210024503-A1 4-OXO-3,4-DIHYDROQUINAZOLINE COMPOUNDS AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION EIF2AK2, CCNI, IRF3 ALDH1A1 2920/4885KDM4E 484/4885MAPT 2477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.